CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-10 | Wu Xiaobin President and COO | Grant or award | +123,370 | 1,274,296 | ||
| 2025-06-10 | Wu Xiaobin President and COO | Grant or award · Share Option (Right to Buy) | +232,245 | 232,245 | ||
| 2025-06-10 | Wang Xiaodong Director | Grant or award 10b5-1 | +98,696 | 5,180,861 | ||
| 2025-06-10 | Wang Xiaodong Director | Option exercise 10b5-1 | +41,760 | $6.50 | $271K | 41,760 |
| 2025-06-10 | Wang Xiaodong Director | Sale 10b5-1 | −2,901 | $261.20 | $758K | 38,859 |
| 2025-06-10 | Wang Xiaodong Director | Sale 10b5-1 | −15,878 | $262.20 | $4.2M | 22,981 |
| 2025-06-10 | Wang Xiaodong Director | Sale 10b5-1 | −16,094 | $263.17 | $4.2M | 6,887 |
| 2025-06-10 | Wang Xiaodong Director | Sale 10b5-1 | −6,787 | $264.08 | $1.8M | 100 |
| 2025-06-10 | Wang Xiaodong Director | Sale 10b5-1 | −100 | $264.85 | $26K | 0 |
| 2025-06-10 | Wang Xiaodong Director | Grant or award · Share Option (Right to Buy) 10b5-1 | +185,796 | 185,796 | ||
| 2025-06-10 | Wang Xiaodong Director | Option exercise · Share Option (Right to Buy) 10b5-1 | −542,880 | 7 | ||
| 2025-06-10 | OYLER JOHN Chief Executive Officer | Grant or award | +185,055 | 8,281,841 | ||
| 2025-06-10 | OYLER JOHN Chief Executive Officer | Grant or award · Share Option (Right to Buy) | +348,374 | 348,374 | ||
| 2025-06-10 | Yi Qingqing Director | Other disposition | −29,614 | 27,326 | ||
| 2025-06-06 | Lee Chan Henry SVP, General Counsel | Sale | −470 | $255.78 | $120K | 230 |
| 2025-06-06 | Lee Chan Henry SVP, General Counsel | Sale | −230 | $256.79 | $59K | 0 |
| 2025-06-06 | Wang Lai Global Head of R&D | Sale | −600 | $250.71 | $150K | 802 |
| 2025-06-06 | Wang Lai Global Head of R&D | Sale | −202 | $251.89 | $51K | 600 |
| 2025-06-06 | Wang Lai Global Head of R&D | Sale | −300 | $253.19 | $76K | 300 |
| 2025-06-06 | Wang Lai Global Head of R&D | Sale | −300 | $255.30 | $77K | 0 |
Page 24 of 71 · 1,406 trades